All In Biotech

Drug Trial Radar · NCT05749588

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping((A Phase II, Open-label, Single-center Platform Study)

Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Mar 30, 2023

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.

Conditions

  • Triple-negative Breast Cancer

Interventions

  • A1: SHR-A1811Drug

    A1: an anti-HER2 antibody-drug conjugate (ADC)

  • A2: SHR-A1811 with Camrelizumab with famitinibDrug

    A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) Camrelizumab: an anti-programmed death-1 (PD-1) antibody

  • B1: TROP2 ADCDrug

    B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC

  • B2: TROP2 ADC with CamrelizumabDrug

    B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC Camrelizumab: an anti-programmed death-1 (PD-1) antibody

  • C1: SHR-A1811Drug

    C1: an anti-HER2 antibody-drug conjugate (ADC)

  • C2: SHR-A1811 with BP102Drug

    C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)

  • D1: TROP2 ADCDrug

    D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC

  • D2: TROP2 ADC with BP102Drug

    D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)

  • E1: SHR-A1811Drug

    E1: an anti-HER2 antibody-drug conjugate (ADC)

  • F1: TROP2 ADCDrug

    F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC

  • G1: SHR-A1811Drug

    G1: an anti-HER2 antibody-drug conjugate (ADC)

  • H1: TROP2 ADCDrug

    H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC

  • E2: SHR-A1811 with everolimusDrug

    E1: SHR-A1811 an anti-HER2 antibody-drug conjugate (ADC) everolimus: an mTOR inhibitor

  • TQB2102 with TQB2868Drug

    TQB2102: an anti-HER2 antibody-drug conjugate (ADC) TQB2868: an anti-PD-1/TGF-β bispecific antibody in all-comer TNBC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR)Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 3 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.